Phuturdex › Diseases › Clear-cell metastatic renal cell carcinoma
Drugs in development · updated 30 October 2026
Clear-cell metastatic renal cell carcinoma: drugs in development
As of 30 October 2026 there are 24 active clinical trials (recruiting or ongoing, phases I–III) on 26 drugs for clear-cell metastatic renal cell carcinoma. 14 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Casdatifan | III | 3 | NCT07011719 |
| ZanzalintinibXL092 | II | 2 | NCT07043608 |
| AB-2100 | I–II | 1 | NCT06245915 |
| EB-701 | I–II | 1 | NCT07551349 |
| PF-08634404 | I–II | 1 | NCT07227415 |
| Selenomethionine | I–II | 1 | NCT05363631 |
| Sodium-Iodide Symporter | II | 1 | NCT07510334 |
| Yivoximab | II | 1 | NCT07488572 |
| ALLO-316 | I | 1 | NCT04696731 |
| ALLO-647 | I | 1 | NCT04696731 |
| BMS-986506 | I | 1 | NCT07195682 |
| NEO-811 | I | 1 | NCT07300241 |
| Pumitamig | I | 1 | NCT07195682 |
| Valemetostat | I | 1 | NCT04388852 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| IpilimumabYERVOY, ipililumab IV | III | 8 | NCT07383441 |
| NivolumabOpdivo, ONO-4538 | III | 8 | NCT07383441 |
| CabozantinibResniben®, Cabometyx® | III | 5 | NCT07011719 |
| AxitinibInlyta®, Axitinib Accord® | III | 4 | NCT07383441 |
| LenvatinibLenvatinib Mesilate Capsules, Levatinib | III | 2 | NCT07383441 |
| PembrolizumabKEYTRUDA, MK-3475 | III | 2 | NCT07383441 |
| FludarabineFludara, FLUDARABIN | I–II | 2 | NCT07551349 |
| EverolimusRAD001, Everoliumus | II | 1 | NCT05012371 |
| Pluvicto177Lu-PSMA-617, Lutetium Lu 177 Vipivotide Tetraxetan | II | 1 | NCT06783348 |
| ToripalimabJS001, Teripalimab | II | 1 | NCT07776717 |
| Cabozantinib S-malateCabometyx®, Cometriq® | I | 1 | NCT05122546 |
| CyclophosphamideCyclophosphamid, Cytoxan | I | 1 | NCT04696731 |
Sorted by most advanced phase and number of active trials.
All 26 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Broader categories
- Kidney disease 38 drugs
- Urologic Diseases 16 drugs
- Female urogenital disease 11 drugs
- Female urogenital diseases and pregnancy complications 3 drugs
- Urogenital Diseases 16 drugs
- Male urogenital disease 19 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: NLM MeSH; NLM MeSH term: C538445 “Clear-cell metastatic renal cell carcinoma”.